EFAVIRENZ- efavirenz tablet, film coated
Mylan Pharmaceuticals Inc.


Efavirenz in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.


2.1 Hepatic Function

Monitor hepatic function prior to and during treatment with efavirenz tablets [see Warnings and Precautions (5.9) ].

Efavirenz tablets are not recommended in patients with moderate or severe hepatic impairment (Child Pugh B or C) [see Warnings and Precautions (5.9) and Use in Specific Populations (8.6)].

2.2 Adults

The recommended dosage of efavirenz tablets is 600 mg orally, once daily, in combination with a protease inhibitor and/or nucleoside analogue reverse transcriptase inhibitors (NRTIs). It is recommended that efavirenz tablets be taken on an empty stomach, preferably at bedtime. The increased efavirenz concentrations observed following administration of efavirenz tablets with food may lead to an increase in frequency of adverse reactions [see Clinical Pharmacology (12.3) ]. Dosing at bedtime may improve the tolerability of nervous system symptoms [see Warnings and Precautions (5.6), Adverse Reactions (6.1), and Patient Counseling Information (17)]. Efavirenz tablets should be swallowed intact with liquid.

Concomitant Antiretroviral Therapy

Efavirenz tablets must be given in combination with other antiretroviral medications [see Indications and Usage (1), Warnings and Precautions (5.3), Drug Interactions (7.1), and Clinical Pharmacology (12.3)].

2.3 Pediatric Patients

It is recommended that efavirenz be taken on an empty stomach, preferably at bedtime. Table 1 describes the recommended dose of efavirenz for pediatric patients 3 months of age or older and weighing between 3.5 kg and 40 kg [see Clinical Pharmacology (12.3) ]. The recommended dosage of efavirenz for pediatric patients weighing 40 kg or greater is 600 mg once daily. For pediatric patients who cannot swallow capsules, the capsule contents can be administered with a small amount of food or infant formula using the capsule sprinkle method of administration.

Table 1: Efavirenz Dosing in Pediatric Patients
Capsules can be administered intact or as sprinkles.
Tablets must not be crushed.

Patient Body Weight

Efavirenz Daily Dose

Number of Capsules * or Tablets and Strength to Administer

3.5 kg to less than 5 kg

100 mg

two 50 mg capsules

5 kg to less than 7.5 kg

150 mg

three 50 mg capsules

7.5 kg to less than 15 kg

200 mg

one 200 mg capsule

15 kg to less than 20 kg

250 mg

one 200 mg + one 50 mg capsule

20 kg to less than 25 kg

300 mg

one 200 mg + two 50 mg capsules

25 kg to less than 32.5 kg

350 mg

one 200 mg + three 50 mg capsules

32.5 kg to less than 40 kg

400 mg

two 200 mg capsules

at least 40 kg

600 mg

one 600 mg tablet OR three 200 mg capsules


Efavirenz Tablets, USP are available containing 600 mg of efavirenz, USP.

The 600 mg tablets are yellow, film-coated, capsule shaped, unscored tablets debossed with MYLAN on one side of the tablet and 233 on the other side.


Efavirenz tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of this product.
Coadministration of efavirenz with elbasvir and grazoprevir is contraindicated [see Warnings and Precautions (5.1) and Drug Interactions (7.1)].


5.1 Drug Interactions

Efavirenz plasma concentrations may be altered by substrates, inhibitors, or inducers of CYP3A. Likewise, efavirenz may alter plasma concentrations of drugs metabolized by CYP3A or CYP2B6. The most prominent effect of efavirenz at steady-state is induction of CYP3A and CYP2B6 [see Dosage and Administration (2.2) and Drug Interactions (7.1)].

5.2 QTc Prolongation

QTc prolongation has been observed with the use of efavirenz [see Drug Interactions (7.3, 7.4) and Clinical Pharmacology (12.2)]. Consider alternatives to efavirenz when coadministered with a drug with a known risk of Torsade de Pointes or when administered to patients at higher risk of Torsade de Pointes.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.